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Systematic Reviews of Animal Experiments Demonstrate
Poor Human Clinical and Toxicological Utility
Andrew Knight
Animal Consultants International, London, UK
Summary — The assumption that animal models are reasonably predictive of human outcomes provides
the basis for their widespread use in toxicity testing and in biomedical research aimed at developing cures
for human diseases. To investigate the validity of this assumption, the comprehensive Scopus biomedical
bibliographic databases were searched for published systematic reviews of the human clinical or toxicological utility of animal experiments. In 20 reviews in which clinical utility was examined, the authors concluded that animal models were either significantly useful in contributing to the development of clinical
interventions, or were substantially consistent with clinical outcomes, in only two cases, one of which was
contentious. These included reviews of the clinical utility of experiments expected by ethics committees to
lead to medical advances, of highly-cited experiments published in major journals, and of chimpanzee
experiments — those involving the species considered most likely to be predictive of human outcomes.
Seven additional reviews failed to clearly demonstrate utility in predicting human toxicological outcomes,
such as carcinogenicity and teratogenicity. Consequently, animal data may not generally be assumed to be
substantially useful for these purposes. Possible causes include interspecies differences, the distortion of
outcomes arising from experimental environments and protocols, and the poor methodological quality of
many animal experiments, which was evident in at least 11 reviews. No reviews existed in which the majority of animal experiments were of good methodological quality. Whilst the effects of some of these problems might be minimised with concerted effort (given their widespread prevalence), the limitations
resulting from interspecies differences are likely to be technically and theoretically impossible to overcome.
Non-animal models are generally required to pass formal scientific validation prior to their regulatory
acceptance. In contrast, animal models are simply assumed to be predictive of human outcomes. These
results demonstrate the invalidity of such assumptions. The consistent application of formal validation
studies to all test models is clearly warranted, regardless of their animal, non-animal, historical, contemporary or possible future status. Likely benefits would include, the greater selection of models truly predictive of human outcomes, increased safety of people exposed to chemicals that have passed toxicity tests,
increased efficiency during the development of human pharmaceuticals and other therapeutic interventions, and decreased wastage of animal, personnel and financial resources. The poor human clinical and
toxicological utility of most animal models for which data exists, in conjunction with their generally substantial animal welfare and economic costs, justify a ban on animal models lacking scientific data clearly
establishing their human predictivity or utility.
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Introduction

United States alone, that many millions of animals
are used worldwide, and that certain trends are
resulting in an increase in laboratory animal use.

Trends in laboratory animal use
Standards for the reporting of laboratory animal use
vary internationally, with many countries failing to
record or publicise statistics on animal use at all. Of
those that do, most record only live animal use, and
fail to record the substantial numbers of animals that
may be killed prior to certain procedures, such as dissection or the collection of organs, tissues or cells.
Hence, making realistic annual estimates of animal
use within biomedical research and toxicity testing is
difficult. Despite these limitations, it remains clear
from consideration of the European Union (EU) and

EU
European Commission (EC) statistics on laboratory
animal use in 25 EU Member States, revealed that
12,117,583 animals were used in 2005, the latest
reporting period (except for France, which provided
figures for 2004). The majority of these were mice
(53.1%), rats (19.3%), cold-blooded animals (15.1%,
consisting of fish [primarily], amphibians and reptiles), and birds (5.4%). As in previous years,
France, Germany and the UK reported the greatest
animal use (1).
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United States
In the USA, laboratory animal use is federally regulated by the Animal Welfare Act 1966 (amended in
1985), which excludes laboratory-bred mice and
rats, as well as non-mammals, from consideration
or protection (2, 3), despite the fact that mice and
rats comprise the overwhelming majority of all laboratory subjects. This impedes the accurate estimation of laboratory animal use in the USA. For
example, although 1,012,713 regulated animals
were used in the Fiscal Year 2006 (4), the latest
reporting period, Carbone (5) estimated that in
excess of 100 million mice are used annually. This
represents a dramatic increase from the 17–22 million vertebrates used in the mid-1980s (6).

Genetically-modified animal use
In recent years, the previous steady decreases in
laboratory animal use have been reversed, in some
countries, mostly as a result of dramatic increases
in the use of genetically-modified (GM) animals.
The production of these GM animals requires substantial breeding, which serves to further increase
the numbers of animals used. Within the UK, for
example, a steady and significant reduction since
1976 stabilised during the early 1990s, and then
reversed. 3,012,032 procedures on living, regulated
animals (vertebrates and one species of octopus,
Octopus vulgaris) were conducted in 2006, the highest number for around 15 years (7). Greater breeding and use of GM animals have contributed to
these increasing numbers (8, 9). In 1995, GM animals were used in 8% of regulated procedures. In
2004, the total was 32%, and in 2006 it was 34%
(1,035,343 regulated procedures; 7). Increased GM
animal use has also been recorded in Germany (10)
and Switzerland (11), where total animal use is also
increasing (11, 12).

Chemical testing programmes
Recently-initiated, large-scale chemical testing programmes are also important drivers of the recent
and probable substantial future increases in laboratory animal use (13, 14). These programmes are
intended to rectify existing knowledge gaps with
regard to the toxicity of chemicals that are produced or imported into the EU and the USA in particularly high quantities (or that otherwise give rise
to special concerns), and are likely to result in the
use of unprecedented numbers of animals in toxicity testing. Included are three programmes initiated
by the US government, and managed by the
Environmental Protection Agency (EPA) since
1998: the High Production Volume (HPV) Challenge Program, the Endocrine Disruptor Screening
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Program, and the Voluntary Children’s Chemical
Evaluation Program. The 2003 EC proposal for the
Registration, Evaluation and Authorisation of
Chemicals (REACH), similarly aims to assess the
toxicity of chemicals produced or imported in high
quantities (15–20). It is reported that the HPV programme, for example, has already subjected over
150,000 animals to chemical tests (21).

Claims supporting laboratory animal use
Biomedical research using laboratory animals is
highly controversial. Advocates frequently claim
that such research is vital for preventing, curing or
alleviating human diseases (e.g. 22, 23), that the
greatest achievements of medicine have been possible only due to the use of animals (e.g. 24), and that
the complexity of humans requires nothing less
than the complexity of laboratory animals to serve
as an effective model during biomedical investigations (e.g. 25). They even claim that medical
progress would be “severely maimed by prohibition
or severe curtailing of animal experiments,” and
that “catastrophic consequences would ensue” (26).
However, such claims are hotly contested (e.g.
27), and the right of humans to experiment on animals has also been strongly contested philosophically (e.g. 28, 29). A growing body of empirical
evidence also casts doubt upon the scientific utility
of animals as experimental models of humans.

Clinical utility of animal models: case studies
Within the field of pharmaceutical development,
case studies exemplifying differing human and animal outcomes — sometimes with severe adverse
consequences for human patients — are sufficiently
numerous to fill entire book chapters (e.g. 30, 31).
A recent notorious example was TGN1412 (also
known as CD28-SuperMAB), a fully-humanised
monoclonal antibody (i.e. a product developed in a
non-human species and protein-engineered to possess specifically-human characteristics) that was
undergoing development for the treatment of
inflammatory conditions, such as leukaemia and
rheumatoid arthritis (32, 33). During a Phase I clinical trial in the UK in 2006, TGN1412 caused severe
adverse reactions, culminating in organ failure
requiring intensive care, in all six volunteers given
the drug, with one volunteer suffering permanent
damage. These effects occurred despite the administration of an expected sub-clinical dose of 0.1
mg/kg — 500 times lower than the 50 mg/kg dose
found not to cause adverse effects in cynomolgus
monkeys. Tests on rhesus macaques, rats and mice
also failed to reveal adverse effects (34, 35).
Another recent notorious example was the arthritis drug, Vioxx, which appeared to be safe, and even
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beneficial to the heart, in animal studies. However,
Vioxx was withdrawn from the global market in
2004, after causing as many as 140,000 heart
attacks and strokes, and over 60,000 deaths, in the
USA alone (36).
Since their commercial introduction in the early
1980s, non-steroidal anti-inflammatory drugs
(NSAIDs) have also had a problematic clinical history. Although apparently safe in year-long studies
in rhesus monkeys, benoxaprofen (Oraflex) produced thousands of serious adverse reactions in
humans, including dozens of deaths, within three
months of its initial marketing (37). Fenclofenac
(Flenac) revealed no toxicity in ten animal species,
yet produced severe liver toxicity in humans, and
was subsequently withdrawn (38). Similar fates
befell some other NSAIDs, including zomepirac
(Zomax; 39), bromfenac (Duract; 40), and phenylbutazone (Butazolidin; 41), which produced adverse
human effects undetected in animal studies.
Numerous other pharmaceuticals have also been
marketed after passing limited clinical trials and
more rigorous animal testing, only to subsequently
be found to cause serious side-effects or death in
human patients. Examples include various antibiotics (e.g. chloramphenicol, clindamycin, temafloxacin), antidepressants (e.g. nomifensine), antivirals
(e.g. idoxuridine), cardiovascular medications (e.g.
amrinone, cerivastatin, mibefradil, ticrynafen), and
many others (e.g. 30, 42–44).
Although 92% of new drugs that pass preclinical
testing, which routinely includes animal tests, fail
to reach the market because of safety or efficacy
failures in human clinical trials (45), adverse drug
reactions detected after drugs have been approved
for clinical use, nevertheless remain common. They
are, indeed, sufficiently common to have been
recently recorded as the 4th–6th leading cause of
death in US hospitals (based on a 95% confidence
interval; 46), a rate considered by investigators to
be “extremely high”.
There are also cases of safe and efficacious
human pharmaceuticals that would not pass rigorous animal testing, because of severe or lethal toxicity in some laboratory animal species. Notable
examples include, penicillin (e.g. 47), paracetamol
(acetaminophen; e.g. 48), and aspirin (acetylsalicylic acid; e.g. 49). More rigorous animal testing
may well have delayed or prevented the use of these
highly beneficial drugs in human patients.
The large number of examples of apparent differences between outcomes in laboratory animals and in
human patients may be the result of several factors.
Flaws may occur during the pharmaceutical development and testing process, in which the design, conduct or interpretation of experiments may fail to
adequately highlight the risks to human patients.
Such flaws are more likely in animal studies than in
human clinical trials, because the experimental quality of the former are usually significantly lower (see
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Results and Discussion). True discordance in results
may also arise from interspecies differences.
Finally, the limited predictivity for wider human
outcomes of human clinical trials may result from
their focus on small groups of healthy young men,
or from insufficient study durations. Particularly in
Phases I–II, small cohorts of young men (20–300)
are typically used, to minimise experimental variability and to avoid the possibility of endocrinological disruption or other risks to women of
reproductive age. Although 1,000–3,000 volunteers
may be used in Phase III trials, the final phase
before marketing (50), it is nevertheless clear that
cohort numbers, study durations or other aspects of
protocol design, conduct or interpretation, are inadequate to detect the adverse side-effects of the large
number of pharmaceuticals that are found to harm
patients after marketing. Longer studies of morebroadly representative human populations would
be more predictive, but would increase the time and
cost of pharmaceutical development, and are resisted by pharmaceutical companies.

The necessity of systematic reviews
The premise that laboratory animal models are generally predictive of human outcomes is the basis for
their widespread use in human toxicity testing, and
in the safety and efficacy testing of putative
chemotherapeutic agents and other clinical interventions. However, the numerous cases of discordance between laboratory animal and human
outcomes suggest that this premise may well be
incorrect, and that the utility of animal experiments for these purposes may not be assured. On
the other hand, only small numbers of experiments
are normally reviewed in case studies, and their
selection may be subject to bias. To provide moredefinitive conclusions, systematic reviews of the
human clinical or toxicological utility of large numbers of animal experiments are necessary.
Experiments included in such reviews should be
selected without bias, via randomisation, or similarly methodical and impartial means.
In support of this concept, Pound and colleagues
(51) commented that clinicians and the public often
consider it axiomatic that animal research has contributed to human clinical knowledge, on the basis of
anecdotal evidence or unsupported claims. These
constitute an inadequate form of evidence, they
asserted, for such a controversial area of research,
particularly given increasing competition for scarce
research resources. Hence, they called for systematic
reviews to examine the human clinical utility of animal experiments, and commenced by examining six
existing reviews, which did not demonstrate the clinical utility expected of the experiments in question.
Soon afterwards, the UK Nuffield Council on
Bioethics stated that, It would… be desirable to
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undertake further systematic reviews and metaanalyses to evaluate more fully the predictability
and transferability of animal models. They called
for these to be undertaken by the UK Home Office,
in collaboration with the major funders of research,
industry associations and animal protection groups
(52).
Since then, several such reviews and meta-analyses have been published, which collectively provide
important insights into the human clinical and toxicological utility of animal models. Their identification and examination was the purpose of this
review.

Methods
The Scopus biomedical bibliographic databases
were searched for systematic reviews of the human
clinical or toxicological utility of animal experiments published in the peer-reviewed biomedical
literature. Among the world’s most comprehensive
databases, they include over 12,850 academic journals, 500 open access journals, 700 conference proceedings, and a total of 29 million abstracts (53).
The Life Sciences database includes over 3,400
titles, and the Health Sciences database includes
over 5,300 titles, including all of Medline, the leading medical and allied health profession database,
which itself contains over 15 million citations from
the mid-1950s onwards, sourced from more than
5,000 biomedical journals from over 80 countries
(54).
All abstracts, titles and key words were searched
for (animal experiment OR animal model OR animal study OR animal trial) AND (clinical trial OR
human outcome OR human relevance OR human
result). The results were limited to articles or
reviews, but no chronological, language or other
limitations were applied. Titles and, where necessary, abstracts or complete papers, were examined,
in order to locate relevant papers. Additional relevant studies were obtained by examination of the
reference lists of the papers retrieved, and by consultation with colleagues working in this field.
To minimise bias, reviews were included only
when they had been conducted systematically, by
using randomisation or similarly methodical and
impartial means to select animal studies. For example, in some cases, all the animal studies within relevant subsets of toxic chemical databases were
examined, without exclusion.
The examination covered only reviews which considered the human toxicological predictivity or utility of animal experiments, their contributions
toward the development of prophylactic, diagnostic
or therapeutic interventions with clear potential for
combating human diseases or injuries, or their consistency with human clinical outcomes. Reviews
which focused, for example, only on the contribu-
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tions of animal experiments toward increased
understanding of the aetiological, pathogenesic or
other aspects of human diseases, or on the clinical
utility of animal experiments in non-human
species, were excluded from consideration.

Results and Discussion
Bibliographic databases are constantly updated.
2,274 articles or reviews were retrieved, by using
the specified search terms, on 1 March 2007. In
total, 27 systematic reviews which examined the
utility of animal experiments during the development of human clinical interventions (20), or in
deriving human toxicity classifications (seven),
were located. Three different approaches that
sought to determine the maximum human clinical
utility that may be achieved by animal experiments,
were of particular interest.

Clinical utility of experiments expected to
lead to medical advances
Lindl and colleagues (55, 56) examined animal experiments conducted at three German universities
between 1991 and 1993, that had been approved by
animal ethics committees, at least partly on the basis
of claims by researchers that the experiments might
lead to concrete advances toward the cure of human
diseases. Experiments were only included where previous studies had shown that the applications of
related animal research had confirmed the hypotheses of the researchers, and where the experiments
had achieved publication in biomedical journals.
For 17 experiments meeting these inclusion criteria, citations were analysed over at least 12 years.
Citation frequencies and types of citing papers were
recorded: whether they were reviews or animalbased, in vitro, or clinical studies. 1,183 citations
were evident, but only 8.2% (97 citations) were in
clinical publications, and only 0.3% (4 citations)
demonstrated a direct correlation between the
results of animal experiments and human outcomes. However, even in these four cases, the
hypotheses that had been verified successfully in
the animal experiment failed in every respect when
applied to humans. None of these 17 experiments
led to any new therapies, or had any beneficial clinical impact during the period examined.
As a result of their analysis, Lindl and colleagues
called for serious, rather than cursory, evaluations
of the likely benefits of animal experiments by animal ethics committees and related authorities, and
for a reversal of the current paradigm, in which animal experiments are routinely approved. Instead of
approving experiments because of the possibility
that benefits might accrue, Lindl and colleagues
suggested that where significant doubt exists, labo-
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ratory animals should receive the benefit of that
doubt, and that such experiments should not, in
fact, be approved.

Clinical utility of highly-cited animal
experiments
Hackam and Redelmeier (57) also used a citation
analysis, but without geographical limitations.
Based on the assumption that findings from highlycited animal experiments would be most likely to be
subsequently tested in clinical trials, they searched
for experiments with more than 500 citations and
published in the seven leading scientific journals, as
ranked by citation impact factor.
Of 76 animal studies located, with a median citation count of 889 (range: 639–2,233), only 36.8%
(28/76) were replicated in randomised human trials.
18.4% (14/76) were contradicted by randomised trials, and 44.7% (34/76) had not translated to clinical
trials. Ultimately, only 10.5% (8/76) of these medical
interventions were subsequently approved for use in
patients, and, as stated previously, even in these
cases, human benefit cannot be assumed, because
adverse reactions to approved interventions are common, and a leading cause of death (46).
A low rate of translation to clinical trials of even
these highly-cited animal experiments was apparent, despite 1992 being the median publication
year, allowing a median of 14 years for potential
translation. For studies that did translate to clinical
trials, the median time for translation was seven
years (range 1–15). The frequency of translation
was not affected by the laboratory animal species
used, the type of disease or therapy under examination, the journal, year of publication, methodological quality, and even, surprisingly, the citation rate.
However, animal studies incorporating dose–
response gradients were more likely to be translated to clinical trials (odds ratio [OR] = 3.3; 95%
confidence interval [CI] = 1.1–10.1).
Although the rate of translation of these animal
studies to clinical trials was low, as Hackam and
Redelmeier stated, it is nevertheless higher than
that of most published animal experiments, which
are considerably less likely to be translated than
these highly-cited animal studies published in leading journals. Furthermore, the selective focus on
positive animal data, whilst ignoring negative
results (optimism bias), was one of several factors
proposed that may have increased the likelihood of
translation beyond that which was scientifically
merited. As Hackam (58) stated, the rigorous metaanalysis of all relevant animal experimental data
would probably significantly decrease the translation rate to clinical trials.
In addition, only 48.7% (37/76) of these highlycited animal studies were considered to be of good
methodological quality. Despite their publication in
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leading scientific journals, few included the random
allocation of animals to test groups, any adjustment
for multiple hypothesis testing, or the blinded
assessment of outcomes. Accordingly, Hackam and
Redelmeier cautioned patients and physicians
about the extrapolation of the findings of even
highly-cited animal research to cases of human disease.

Clinical utility of chimpanzee experiments
Chimpanzees are the species most closely related to
humans, and consequently, are considered to be the
laboratory animals most likely to provide results
which are predictive of human outcomes. Hence, in
2005, I conducted a citation analysis of the human
clinical utility of chimpanzee experiments (59).
I searched three major biomedical bibliographic
databases, and located 749 papers published
between 1995 and 2004, which described experiments on captive chimpanzees or their tissues.
Although published in the international scientific
literature, the vast majority of these experiments
were conducted within the USA (60). To obtain 95%
CIs with an accuracy of at least plus or minus 10%,
when estimating the proportion of chimpanzee
studies subsequently cited by other published
papers, a subset of at least 86 chimpanzee studies
was required (61–63).
Of 95 published randomly-selected studies on
chimpanzees, 49.5% (47/95) were not cited by any
subsequent papers, demonstrating minimal contributions toward the advancement of biomedical
knowledge. This is of particular concern, because it
can be assumed that research judged to be of lesser
value was not published. Hence, it appears that the
majority of chimpanzee research generates data of
questionable value, which make little obvious contribution toward the advancement of biomedical
knowledge.
35.8% (34/95) of the 95 published chimpanzee
studies were cited by 116 papers that clearly did not
describe well-developed methods for combating
human diseases. Only 14.7% (14/95) of them were
cited by 27 papers that had abstracts which indicated well-developed prophylactic, diagnostic or
therapeutic methods for combating human diseases. However, a detailed examination of these 27
medically-oriented papers revealed that in vitro
studies, human clinical and epidemiological studies,
molecular assays and methods, and genomic studies, contributed most to their development. 63.0%
(17/27) were wide-ranging reviews of 26–300
(median 104) references, to which these cited chimpanzee studies made very small contributions.
Duplication of human outcomes, inconsistency with
other human or primate data, and other causes,
resulted in the absence of any chimpanzee study
able to demonstrate an essential contribution, or, in
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most cases, a significant contribution of any kind,
toward the development of the medical method
described.
Despite the low utility of chimpanzee experiments in advancing human health which was indicated by these results, it remains true that
chimpanzees are the species most closely related to
human beings. Hence, it is highly likely other laboratory species are even less useful as experimental
models of humans in biomedical research and toxicity testing.

Clinical utility of stroke and head injury
models
Despite the existence of literature on the efficacy of
more than 700 drugs in treating experimental models of stroke (artificially-induced focal cerebral
ischaemias; 64), only recombinant tissue plasminogen activator (rt-PA) and aspirin have convincingly
demonstrated efficacy in human clinical trials of
treatments for acute ischaemic stroke (65–67).
Hence, Macleod and colleagues (64) stated that,
This failure of putative neuroprotective drugs in
clinical trials represents a major challenge to the
doctrine that animals provide a scientifically-valid
model for human stroke. At least 10 published systematic reviews have described the poor human
clinical utility of animal experimental models of
stroke and head injuries (64, 68–76).
In some cases, clinical trials proceeded, despite
equivocal evidence of efficacy in animal studies. For
example, Horn and colleagues (68) systematically
reviewed 20 animal studies on the efficacy of
nimodipine, of which only 50% showed beneficial
effects following treatment. They concluded that,
...the results of this review did not show convincing
evidence to substantiate the decision to perform trials with nimodipine in large numbers of patients.
These clinical trials also demonstrated equivocal
evidence of efficacy, and furthermore, proceeded
concurrently with the animal studies, despite the
fact that the latter are intended to be conducted
prior to clinical trials, to facilitate the detection of
potential human toxicity.
O’Collins and colleagues (69) conducted a very
large review of 1,026 experimental drugs for acute
stroke that had been tested in animal models. They
found that the effectiveness in animals of 114 drugs
chosen for human clinical use was no greater than
that of the remaining 912 drugs not chosen for clinical use, thereby demonstrating that effectiveness
in animal models had no measurable effect on
whether or not these drugs were selected for human
clinical use. Accordingly, O’Collins and colleagues
questioned whether the most efficacious drugs are,
in fact, being selected for clinical trials, and called
for greater rigour in the conduct, reporting, and
analysis of animal experiments.
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In many cases, animal models did indicate efficacy,
but this did not translate to humans. In a few
reviews, the authors speculated on the possible
causes. For example, Jonas and colleagues (70)
hypothesised that the poor clinical efficacy of neuroprotectants which had been found to be successful in
animal models, was due to differences in the timing of
the initiation of treatment. Curry (71) hypothesised
that the human clinical failure of fourteen neuroprotective agents which were successful in animal models, was due to the antagonism of glutamate — which
may be associated with neuroprotection — by drug
treatment in clinically-normal individuals. He therefore proposed that clinical trials should be restricted
to real stroke patients, who experience elevated
plasma glutamate levels. However, such speculation
has not resulted in improvements in the poor clinical
record of neuroprotectants which were previously
found to be successful in animal models.
The utility of the majority of these animal studies
also appears to have been impeded by their poor
methodological quality. Examples include: animal
studies on the efficacy of melatonin (64); 20 animal
studies on the efficacy of nimodipine (68); 29 animal
studies on the efficacy of FK506 (72); 45 animal studies on five compounds from different classes of
alleged neuroprotective agents — clomethiazole,
gavestinel, lubeluzole, selfotel, and tirilazad mesylate
(73); 25 animal studies on the efficacy of nitric oxide
(NO) donors and L-arginine (74); and 73 animal studies of the efficacy of NO synthase inhibitors (75).
The methodological quality of animal studies was
typically scored on the basis of the presence of characteristics such as: appropriate animal models (aged,
diabetic or hypertensive animals are considered to
more-closely model human stroke patients); power
calculations of sample sizes; random allocation to
treatment and control groups; use of a clinically-relevant time window for commencement of treatment;
blinded drug administration; use of anaesthetics
without significant intrinsic neuroprotective activity
(ketamine, for example, may alter neuroprotective
activity); blinded induction of ischaemia (given that
the severity of induced infarcts may be subtly
affected by knowledge of treatment allocation);
blinded outcome assessment; assessment of both
infarct volume and functional outcome; adequate
monitoring of physiological parameters; assessment
during both the acute (e.g. one to six days) and
chronic (e.g. seven to 30 days) phases; statement of
temperature control; compliance with animal welfare regulations; peer-reviewed publication; and conflict of interest statements. Typically, one point was
given for the presence of each characteristic. For
example, The Stroke Therapy Academic Industry
Roundtable recommendations for standards with
regard to preclinical and restorative drug development involve an eight-point scale (68, 77).
Median quality scores were: four out of 10 (13
studies; range zero to six [64]); four out of 10 (29

Poor human clinical and toxicological utility of animal experiments

studies; range zero to seven [72]); three out of 10
(45 studies [73]); and three out of 8 (73 studies;
range one to six [75]). Common deficiencies
included lack of: sample size calculations, aged animals or those with appropriate co-morbidities, randomised treatment allocation, blinded drug
administration, blinded induction of ischaemia,
blinded outcome assessment, and conflict of interest statements. Some studies also used ketamine
anaesthesia, and there was also substantial variation in the parameters assessed.
van der Worp and colleagues (73), for example, concluded that the collective evidence for neuroprotective efficacy which formed the basis for 21 clinical
trials, was obtained in animal studies with a methodological quality that would not, in retrospect, justify
such a decision. Wilmot and colleagues (74) also
found considerable variations in animal experiment
protocols, which concerned: animal species; physiological parameters (such as blood pressure); drug
administration (timing, dosage, and route); surgical
methodology; and duration of ischaemia. Statistical
analysis (Egger’s test) also revealed the likely existence of publication bias (an increased tendency to
publish studies in which a treatment effect is apparent, or a decreased tendency to so publish, e.g. resulting from commercial pressures, particularly in the
case of patented drugs under development). Macleod
and colleagues (64) commented that, These deficiencies apply to most, if not all, of the animal literature.
This is of particular concern, because Macleod and
colleagues (72) reported that efficacy was apparently
lower in higher quality studies, which raised concerns
that the apparent efficacy may have been artificially
elevated by factors such as poor methodological quality and publication bias.
A related review, not limited solely to stroke, exemplified some of these issues. Perel and colleagues (76)
examined therapeutic interventions with unambiguous evidence of a treatment effect (benefit or harm),
in clinical trials related to the following: corticosteroidal treatment for head injury; anti-fibrinolytics
for the treatment of haemorrhage; thrombolysis, and
also tirilazad, for the treatment of acute ischaemic
stroke; antenatal corticosteroids in the prevention of
neonatal respiratory distress syndrome; and bisphosphonates in the treatment of osteoporosis. They
found that three interventions had similar outcomes
in animal models, whilst three did not, suggesting
that the animal studies did not reliably predict the
human outcomes. Perel and colleagues reported that
the animal studies varied in methodological quality
and sample sizes, that randomisation and blinding
were rarely reported, and that publication bias was
evident.
Clinical utility of other animal experiments
Of seven systematic reviews on the utility of animal
models in other clinical fields identified by this
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review (78–85, of which 79 and 80 described a single review), in only two cases — one of which was
contentious — did the animal models appear to be
clearly useful in the development of human clinical
interventions, or substantially consistent with
human clinical outcomes.
As in the case of stroke, some clinical trials proceeded, despite equivocal evidence of efficacy in animal studies. Upon systematically reviewing the
effects of Low Level Laser Therapy (LLLT) on
wound healing in 36 cell or animal studies, Lucas
and colleagues (78) found that an in-depth analysis
of studies with the highest methodological quality
showed no significant pooled treatment effect.
Despite this, the clinical trials proceeded. Furthermore, almost from the beginning of LLLT investigations, animal experiments and clinical studies
occurred simultaneously, rather than sequentially.
The human trials also failed to demonstrate significant benefits.
Roberts and colleagues (79), and Mapstone and
colleagues (80), all systematically reviewed a group
of 44 randomised, controlled animal studies on the
efficacy of fluid resuscitation in bleeding animals. A
previous systematic review by some of these investigators of clinical trials of fluid resuscitation had
found no evidence that the practice improved outcomes, and had even identified the possibility that
it might be harmful (86). In this later review
(79–80), they found that fluid resuscitation reduced
mortality in animal models of severe haemorrhage,
but increased mortality in those with less severe
haemorrhage.
After clinical trials in humans failed to provide
evidence of benefit, Lee and colleagues (81) conducted a systematic review and meta-analysis of
controlled trials of endothelin receptor blockade in
animal models of heart failure. Meta-analysis failed
to provide evidence of overall benefit, and indicated
increased mortality with early administration.
In their investigation of the contributions of
human clinical trial results and analogous experimental studies to asthma research — one of the
most common and heavily-investigated of modern
diseases — Corry and Kheradmand (82) demonstrated that failure to conduct and analyse the
results of animal studies before proceeding to clinical trials is not uncommon: Research along two
fronts, involving experimental models of asthma
and human clinical trials, proceeds in parallel,
often with investigators unaware of their counterpart’s findings.
The clinical utility of animal models is clearly
questionable in such cases, in which clinical trials
proceed concurrently with, or prior to, animal studies, or continue, despite equivocal evidence of efficacy in the animals.
As in the case of stroke, the clinical utility of the
majority of these animal studies also appears to
have been limited by their poor methodological
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quality. Examples include: 36 cell or animal studies
on the effects of LLLT on wound healing (78); 44
studies on the efficacy of fluid resuscitation in
bleeding animals (79–80); and studies on the efficacy of endothelin receptor blockade in animal models of heart failure (81). Common flaws included
inadequate sample sizes, leaving studies underpowered, and lack of randomisation and blinding.
In some cases, obvious deficiencies within the
animal models were identified. In commenting on
the clinical relevance of animal models for testing
the effects of LLLT on wound healing, Lucas and
colleagues (78) noted that the animal models
excluded common problems associated with wound
healing in humans, such as ischaemia, infection,
and necrotic debris.
Difficulties were also apparent, in translating
animal outcomes to human clinical protocols, in at
least one case. Lazzarini and colleagues (83)
reviewed experimental studies on osteomyelitis, to
ascertain their impacts on the systemic antibiotic
treatment of human osteomyelitis. Although they
found that most of the animal models reviewed
were reproducible and dependable, they also found
that the human predictivity of these studies was
unclear, and was possibly undermined by difficulties in establishing the right dose regimen in the
animals. Although they considered that the use of
antibiotic combinations was associated with better
outcomes in the majority of animal studies, and
that these studies did provide indications of appropriate minimum treatment durations, they concluded that these studies had limited relevance to
clinical practice.
In two cases, reviewers reported that animal and
human outcomes were substantially consistent,
although in one case this conclusion was contentious. While reviewing therapeutic approaches
to streptococcal endocarditis, Scheld (84) reported
good overall correlations among results obtained by
in vitro susceptibility testing (especially killing
kinetics in broth), in animal experiments, and in
clinical trials on different antimicrobial regimens in
humans with streptococcal endocarditis.
To investigate the efficacy of rodent models of
carcinogenesis in predicting treatment outcomes in
humans, Corpet and Pierre (85) conducted a systematic review and meta-analysis of colon cancer
chemoprevention studies involving the use of
aspirin, β-carotene, calcium, and wheat bran, in
rats, mice and humans. Controlled intervention
studies on the recurrence of adenomas in human
volunteers were compared with chemoprevention
studies of carcinogen-induced tumours in rats, and
of polyps in Min (Apc[+/–]) mice. 6,714 humans,
3,911 rats and 458 mice were included in the metaanalyses. Corpet and Pierre found that comparable
results were achieved in rats and humans with
aspirin, calcium, β-carotene, and wheat bran.
Comparable results were found in Min mice and
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humans with aspirin, but discordant results were
obtained with calcium and wheat bran (the equivalent β-carotene results were not available). Corpet
and Pierre concluded that these results suggest that
the use of the rodent models can roughly predict
treatment effects in humans, but that the prediction is not accurate for all agents, and that the carcinogen-induced rat model is more predictive than
the Min mouse model. However, relatively few
agents were tested, and two of the three agents
tested in mice produced different outcomes in
humans, so the conclusion that rodents are predictive of human treatment effects, albeit only
roughly, is itself contentious.

Toxicological utility: carcinogenicity
Due to the limited availability of data on human
exposure, the identification and regulation of exposure to potential human toxins has traditionally
relied heavily on animal studies. However, systematic reviews have indicated that the utility of animal studies for these purposes is lacking in the
fields of carcinogenicity (at least five reviews:
87–91) and teratology (one review: 92). No systematic review demonstrated a contrary result. The
sensitivities of animal models to a range of human
toxicities (i.e. the ability to identify them) highlighted by one review (93) generally appears to be
accompanied by poor human specificity (i.e. the
ability to correctly identify human non-toxins),
resulting in a high incidence of false-positive
results.

EPA survey
The regulation of human exposure to potentially
carcinogenic chemicals constitutes society’s most
important use of animal carcinogenicity data. In
2004, to examine the utility of animal carcinogenicity data in protecting public health, I surveyed the
EPA’s Integrated Risk Information System (IRIS)
chemicals database. This database contains the
environmental contaminants of greatest concern in
the USA, together with their animal, and, in a small
minority of cases, human toxicity data, along with
the human toxicity assessments based on this
pooled data. However, of the 160 IRIS chemicals
lacking even limited human exposure data, but possessing animal data, for which human toxicity
assessments existed, the EPA considered the animal carcinogenicity data to be inadequate to support a classification of probable human carcinogen
or non-carcinogen in the majority of cases (58.1%,
93/160; 95% CI: 50.4–65.5; 87).
Furthermore, data from the World Health
Organisation’s International Agency for Research
on Cancer (IARC) indicated that the true utility of
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animal carcinogenicity data for deriving human carcinogenicity assessments is actually substantially
lower than that indicated solely by EPA assessments. Of 128 chemicals with human or animal
data assessed by both the EPA and the IARC,
human carcinogenicity classifications were consistent between the two agencies only for the 17 chemicals for which at least limited human data were
available. For those 111 chemicals for which the
classification was primarily reliant on animal data,
the EPA was much more likely than the IARC to
assign carcinogenicity classifications indicative of
greater human risk (p < 0.0001; 87).
The IARC is a leading international authority on
carcinogenicity assessments, and the significant differences between its human carcinogenicity classifications and those of the EPA, for identical
chemicals, indicate that: i) in the absence of significant human data, the EPA is over-reliant on animal
carcinogenicity data; ii) as a result, the EPA tends
to over-predict carcinogenic risk; and iii) the true
predictivity for human carcinogenicity of animal
data is even poorer than that indicated by EPA figures alone. EPA policy erroneously assuming that
tumours in animals are indicative of human carcinogenicity, was implicated as a primary cause of
these errors, which have substantial US public
health implications concerning the regulation of
human exposures to environmental contaminants
(87).

IARC Monographs survey
The poor human predictivity of animal carcinogenicity studies was also demonstrated in 1993 by
Tomatis and Wilbourn (88), who surveyed the 780
chemical agents or exposure circumstances evaluated and listed within Volumes 1–55 of the IARC
Monographs series (94). Of these, 502 (64.4%) had
definite or limited evidence of animal carcinogenicity, and 104 (13.3%) were assessed as definite or
probable human carcinogens. Virtually all of the
latter group would, of course, have been members
of the former; so at least 398 animal carcinogens
were assessed and considered not to be definite or
probable human carcinogens.
The positive predictivity of a test is the proportion of positive outcomes that are truly positive for
the characteristic being tested for, while the falsepositive rate refers to the proportion that are not.
Hence, based on these IARC figures, the positive
predictivity of the animal bioassay for definite or
probable human carcinogens was, at best, only
20.7% (104/502), while the false-positive rate was at
least 79.3% (398/502).
More-recent IARC classifications indicate little
improvement in the positive predictivity of the animal bioassay for human carcinogens. By 1 January
2004, a decade later, only 105 additional agents had
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been added to the 1993 number, yielding a total of
885 agents or exposure circumstances listed in the
IARC Monographs (95). The proportion of definite
or probable human carcinogens had increased only
slightly, from 13.3% in 1993 to 17.1% in 2004.

The NTP and other surveys
Surveys by other investigators have also demonstrated the poor human predictivity of animal carcinogenicity data. After examining the studies on
471 substances contained within the US National
Toxicology Program (NTP) carcinogenicity database as of 1 July 1998, Haseman (89) concluded
that, although 250 (53.1%) produced carcinogenic
effects in at least one sex–species group, the actual
proportion which posed a significant carcinogenic
risk to humans was probably far lower, for reasons
such as interspecies differences in mechanisms of
carcinogenicity.
Similarly, around half of all chemicals tested on
animals and included in the comprehensive
Berkeley-based carcinogenic potency database,
whether natural or synthetic, gave positive results
(89). Rall (96) estimated that only around 10% of
chemicals are truly carcinogenic to humans. Ashby
and Purchase (97) speculated that all chemicals
would eventually display some carcinogenic activity, if tested in sufficient rodent strains. Even common table salt has been classified as a tumour
promoter in rats (98).
Fung and colleagues (99) estimated that, if all the
75,000 chemicals in use were tested for carcinogenicity via the standard NTP bioassay, significantly less than 50% would prove carcinogenic in
animals, and less than 5–10% would warrant further investigation. They suggested that the higher
positivity rate recorded is due to chemical selection
based on a priori suspicion of carcinogenicity.
However, examination of the carcinogenicity literature reveals that chemicals are selected for study
for many reasons other than a priori suspicion,
including production volumes, occupational and
environmental exposure risks, and investigations of
mechanisms of carcinogenesis (100). Despite this,
the positivity rate of the carcinogenicity bioassay in
the general literature remains around 50% (101).
Huff (90) demonstrated a significant variation in
carcinogenicity test results between two major carcinogenicity testing programmes, at the NTP
(Research Triangle Park, NC, USA) and the Ramazzini Foundation (RF; Bentivoglio, Italy). Both laboratories had carried out several hundred chemical
carcinogenesis bioassays: around 500 at the NTP,
and 200 at the RF. Of these, 21 chemicals were evaluated by both laboratories, of which published
results were available for 14. The results were
inconsistent for 3 of these 14 chemicals (21.4%),
which had been declared carcinogenic by one labo-

650

ratory but not the other, questioning the reliability
of these assays. Of the remaining 11 chemicals,
both laboratories found nine to be carcinogenic, and
two not to be carcinogenic.
Possible causes for such different toxicity results
between laboratories include differences in: the test
species, strain, age or gender; the quantity, duration and consistency of dosing; the route and
method of administration; diet and laboratory environmental conditions; and the criteria used for the
assessment of toxicity.
Ennever and Lave (91) demonstrated that neither of the two commonly-used interpretations of
rodent carcinogenicity data provide valid conclusions about human carcinogenicity. If a risk avoidance interpretation is used, in which any positive
result in male or female mice or rats is considered
positive, then nine of the 10 known human carcinogens among the hundreds of chemicals tested by the
NTP are positive (102), but so are an implausible
22% of all chemicals tested (99). If a less risk-sensitive interpretation is used, whereby only chemicals
positive in both mice and rats are considered positive, then only three of the six known human carcinogens tested in both species are positive (102).
The former interpretation could result in the needless denial of potentially useful chemicals to society,
while the latter could result in widespread exposure
to undetected human carcinogens.

Toxicological utility: teratogenicity
In 2005, my colleagues and I published an extensive
survey examining the human predictivity of animal
teratogenicity testing (92). We examined nearly
every putative teratogen tested in more than one
species, including 1,396 studies. Data for 11 groups
of known human teratogens tested in 12 animal
species were analysed. Discordance between species
was apparent in just under 30% of these 1,396
reports. Almost a quarter of all the outcomes in the
six main species used (mouse, rat, rabbit, hamster,
primate and dog) were equivocal. For known human
teratogens, there was high variability in positive predictivity between species, the mean of which was
only 51% — hardly better than tossing a coin. Some
species exhibited a high false-negative rate. Only
around half of these known human teratogens were
teratogenic in more than one primate species. Fewer
than one in 40 of the substances designated as potential teratogens from animal studies, were conclusively linked to human birth defects.
We concluded that the poor human predictivity of
animal-based teratology warrants the cessation of
animal testing, and that resources should be reallocated into the further development and implementation of quicker, cheaper and more reliable,
scientifically validated alternatives, such as the
embryonic stem cell test.
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Toxicological utility: various
Under the auspices of the International Life
Sciences Institute’s Health and Environmental
Sciences Institute, Olsen and colleagues (93) sought
to determine the extent to which various types of
human toxicities evident during clinical trials could
be predicted from standard toxicology studies.
Based on a multi-company database of 131 pharmaceutical agents with one or more human toxicities
identified during clinical trials, they reported a
true-positive prediction rate of animal models for
human toxicity of 69%, and also that study results
from non-rodent (dog, primate) species have good
potential to identify human toxicities from many
therapeutic classes.
These results concur with those of the other toxicity reviews described. Animal studies are often
reasonably sensitive for human toxins. However,
their human predictivity and toxicological utility
are limited by their poor human specificity, which
results in high false-positive rates.

Causes of the poor human utility of animal
models
When evaluated overall, these 27 systematic reviews
clearly do not support the widely-held assumptions of
animal ethics committees and the opinions of advocates of animal experimentation, that laboratory animal use is generally beneficial in the development of
human therapeutic interventions and the assessment
of human toxicity. On the contrary, they frequently
demonstrate that animal experiments are of low utility for these purposes. This appears to result both
from limitations of the animal models themselves,
and also from the poor methodological quality and
statistical design of many animal experiments.

Biomedical research
Chimpanzees are our closest living relatives, but
despite great similarities between the structural
regions of chimpanzee DNA and human DNA, important differences between the regulatory regions exert
an “avalanche” effect on large numbers of structural
genes (103). Despite nucleotide difference between
chimpanzees and humans of only 1–2%, this effect
results in differences of around 20%, in terms of protein expression (104), representing a marked phenotypic differences between the species. These
differences manifest as: altered susceptibility to the
aetiology and progression of various diseases; differences in the absorption, tissue distribution, metabolism, and excretion of chemotherapeutic agents; and
differences in the toxicity and efficacy of pharmaceuticals and other agents (59, 103). Such effects appear
to be responsible for the demonstrated inability of
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most chimpanzee research to contribute substantially to the development of methods which are efficacious in combating human diseases (59).
Other laboratory animal species are much less
similar to humans, both genetically and phenotypically, and are therefore less likely to be useful for
accurately modelling the progression of human diseases or of human responses to chemicals and putative chemotherapeutic agents.

Toxicity testing
Rodents are by far the most common laboratory
animal species used in toxicity studies. Several factors contribute to the demonstrated inability of
rodent bioassays to reliably predict human toxicity.
The stresses incurred during handling, restraint,
other routine laboratory procedures, and particularly, the stressful routes of dose administration
common to toxicity tests, alter immune status and
disease predisposition in ways which are very difficult to accurately predict, and which distort the progression of diseases and responses to chemicals and
putative chemotherapeutic agents (105, 106).
In addition, animals have a broad range of physiological defences against general toxic insults, such
as epithelial shedding and inducible enzymes,
which commonly prove effective at environmentally
relevant doses, but which may be overwhelmed at
the high doses commonly applied in routine toxicity
testing (101). Carcinogenicity assays, in particular,
involve chronic, high level dosing. This may result,
inter alia, in insufficient rest intervals between
doses for the effective operation of DNA and tissue
repair mechanisms, which, with the unnatural elevation of cell division rates during ad libitum feeding, may predispose the animals to mutagenesis and
carcinogenesis. Lower doses, greater intervals
between exposures, shorter total periods of exposure, and intermittent feeding, which represent a
more realistic approach to the environmental exposure of humans to most potential toxins, might not
result in toxic changes at all (106).
Finally, differences in rates of absorption and
transport mechanisms between test routes of
administration and other important human routes
of exposure, and the considerable variability of
organ systems in response to toxic insults, between
and within species, strains and genders, render profoundly difficult any attempt to accurately predict
human hazard on the basis of animal toxicity data
(106).

Methodological quality
At least 11 systematic reviews (57, 64, 68, 72–76,
78–81 [of which, 79 and 80 described a single
review]) demonstrated the poor methodological
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quality of many of the animal studies examined,
and none of the reviews demonstrated good
methodological quality in a majority of studies.
While the omission of study details due to publication space constraints may artificially lower apparent quality, the prevalence of such deficiencies
exceeds that which might reasonably be expected,
and is, accordingly, grounds for considerable concern.
Common deficiencies included lack of: sample
size calculations, sufficient sample sizes, appropriate animal models (e.g. aged animals or those with
appropriate comorbidities), randomised treatment
allocation, blinded drug administration, blinded
induction of ischaemia in the case of stroke models,
blinded outcome assessment, and conflict of interest statements. Some studies also used anaesthetics
that may have altered the experimental outcomes,
and substantial variation was evident in the parameters assessed.
These deficiencies limited the clinical utility of
these studies in various significant ways. For example, it is well established that studies lacking randomisation or blinding often over-estimate the
magnitude of the effects of treatments (107–109).
Bebarta and colleagues (110) described the impacts
of lack of randomisation or blinding on estimations
of the significance of treatment effects in 389 animal studies and in 2,203 cell line studies. They
found that studies lacking randomisation or blinding, but not both, were more likely to report a treatment response than studies that used these
measures (OR = 3.4; 95% CI = 1.7 to 6.9, and OR =
3.2; 95% CI = 1.3 to 7.7, respectively), and that
studies lacking both randomisation and blinding
were even more likely to report a treatment
response (OR = 5.2; 95% CI = 2.0 to 13.5).

Statistical design
Insufficient sample sizes left many studies underpowered, limiting the statistical validity of the
study conclusions. Animal lives and other resources
may also be wasted, if experiments subsequently
require repetition as a result. As stated by the UK
Medical Research Council (111), The number of animals used… must be the minimum sufficient to create adequate statistical power to answer the question
posed.
According to Balls and colleagues (112), however,
…surveys of published papers, as well as more anecdotal information, suggest that more than half of the
published papers in biomedical research have statistical mistakes, many seem to use excessive numbers
of animals, and a proportion are poorly designed.
Festing (113) similarly stated that, Surveys of published papers show that there are many errors, both
in the design of the experiments and in the statistical analysis of the resulting data. This must result
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in a waste of animals and scientific resources, and it
is surely unethical. De Boo and Hendriksen (114)
noted the tendency to alter animal numbers based
on scientifically irrelevant issues, such as availability or cost.
Factors that should be considered when calculating appropriate sample sizes include: detectability
threshold (the size of the difference between treatment groups considered significant); known or
expected data variation; the required significance of
the test (‘p’ or ‘α’: the probability of a Type I error
— assuming a difference where none exists); the
acceptable probability of assuming no difference
where one does exist (‘β’, a Type II error. The
‘power’ of an experiment = 1–β; 0.8 is the usual
choice); and the type of statistical analysis to which
the data will be subjected. Smaller thresholds,
greater data variation, smaller acceptable error
probabilities (greater power), and certain statistical
tests for differences, all require larger samples.
No universal rule for calculating correct sample
sizes exists (114). Festing (115), for example,
describes two methods, the preferred ‘power calculation,’ and the ‘resource equation.’ Power calculations use formulae which are available in
interactive computer programmes (e.g. 116, 117),
and calculate the minimum sample sizes required to
detect treatment effects with specified degrees of
certainty. Mead’s ‘resource equation’ (118) calculates sample sizes by using degrees of freedom, and
incorporates statistical parameters, such as treatment effects, block effects and error degrees of freedom.
Strategies should also be considered for minimising animal numbers without unacceptably compromising statistical power. Several of these strategies
aim to decrease data variability by minimising heterogeneity in experimental environments and protocols. This can be achieved by: i) the appropriate
use of environmental enrichment, aimed at decreasing physiological variation resulting from barren
laboratory housing and stressful procedures; ii)
choosing, where possible, to measure variables with
relatively low inherent variability; iii) the use of
genetically homogeneous (isogenic or inbred) or
specified pathogen-free animal strains; and iv)
screening raw data for obvious errors or outliers
(105, 114, 119–122).
Meta-analysis involves the aggregation and statistical analysis of suitable data from multiple
experiments. For some purposes, treatment and
control groups can be combined, permitting group
numbers to be minimised. Although new information can be derived through meta-analysis, more
frequently, the results allow the refinement of
existing knowledge. By designing experiments and
reporting protocols to maximise their utility for
later meta-analyses, the benefit of individual randomised controlled experiments can be maximised
(123). Strategies such as these, aimed at maximis-
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ing the statistical power of small samples, are particularly appropriate when marked ethical, cost or
practical constraints limit the number of animals
that may be used (e.g. in experiments involving
non-human primates).
Finally, the appropriate statistical analysis of the
resultant data should be closely linked to the experimental design, and to the type of data produced
(124). The relatively poor statistical knowledge of
many animal researchers may be the cause of the
high prevalence of poor sample size choices in animal studies. Solutions could include the training of
researchers in statistics, and the direct input of
statisticians in experimental design and data analysis (114, 125).

Raising standards: evidence-based medicine
Evidence-based medicine (EBM) bases clinical decisions on methodologically-sound, prospective, randomised, blinded, and controlled clinical trials. The
gold standard for EBM is large prospective epidemiological studies, or meta-analyses of randomised and
blinded, controlled clinical trials (126). The application to animal experiments of the EBM standards
which are currently applied to human clinical trials,
would make the results more robust and would
increase their applicability (76, 127–130). However,
mechanisms would be needed to ensure compliance
with such standards. Compliance could, for example,
be made a prerequisite for research funding, ethics
committee approval, and the publication of results.
These measures would require the education and cooperation of funding agencies, ethics committees and
journal editors.
The UK Medical Research Council requires
researchers who are planning clinical trials, to reference systematic reviews of related previous work
before they are permitted to proceed (51). To facilitate the detection of toxicity and of potentially efficacious drugs, such reviews should also include all
relevant animal research (76). A similar requirement to reference, or where necessary, conduct, systematic reviews of relevant animal studies, prior to
the commencement of further animal studies,
would encourage a more complete and impartial
assessment of the existing evidence (51).
Mechanisms are also needed to encourage the
reporting of negative results. The negative results
of preclinical studies are much more likely to
remain unpublished than are the negative results of
clinical trials (131). In a systematic review of studies on the efficacy of nicotinamide in combating
experimentally-induced stroke, comparisons published only in abstract form gave a significantly
lower estimate of effect size than those published in
full, demonstrating publication bias (132). van der
Worp and colleagues (73) commented on the pressure to obtain and publish positive results: It is
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therefore conceivable that the career of a preclinical
investigator is more dependent on obtaining positive
results, than that of a clinical trialist.

Fundamental constraints on the human
utility of animal models
Strategies designed to increase the full and impartial examination of existing data before conducting
animal studies, to improve their methodological
quality, and to decrease bias during the publication
of results, would minimise the consumption of animal, financial and other resources within studies of
questionable merit and quality, and would increase
the potential utility of animal data in addressing
human situations and problems. However, the poor
human clinical or toxicological utility of many animal experiments is unlikely to result solely from
their poor methodological quality, or from publication bias. As stated by Perel et al. (76), the failure of
animal models to adequately represent human disease may be another fundamental cause, which, in
contrast, could be technically and theoretically
impossible to correct.
The genetic modification of animal models
through the addition of foreign genes (transgenic
animals) or the inactivation or deletion of genes
(knockout animals) is being attempted, to make
them more-closely model humans. However, as well
as being technically very difficult to achieve, such
modification may not permit clear conclusions, due
to a large number of factors, including those reflecting the intrinsic complexity of living organisms,
such as the variable redundancy of some metabolic
pathways between species (133). Furthermore, the
animal welfare burdens incurred during the creation and use of GM animals are particularly high
(134).

Implications for scientific validation of
experimental models
Proposed non-animal test models are generally
required to pass formal scientific validation before
their use is widely or officially accepted.
Pharmaceutical licensing agencies, for example, are
generally unwilling to accept non-animal test data
as evidence of the human safety of proposed new
pharmaceuticals, until the test models used have
been scientifically validated.
Scientific validation has traditionally involved
the demonstration, in multiple independent laboratories, that the test in question is relevant and reliable for its specified purpose (practical validation;
135), such as the prediction of a certain in vivo outcome. It should also be preceded by an evaluation of
the necessity for the test and of the adequacy of its
development (136, 137). A three-stage prevalidation
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process should be utilised to improve the efficiency
of the formal validation process, by ensuring satisfactory protocol refinement and transferability, and
test performance (138).
However, it is not always scientifically necessary,
or even logistically possible, to conduct multi-centre
practical studies. Hence weight-of-evidence validation, also known as validation by retrospective
analysis (139, 140), may be conducted, based on the
assessment of existing data in a structured, systematic and transparent manner, provided that data of
sufficient quantity and quality are available (141).
Regardless of the approach taken, the criteria
required for formal validation are comprehensive
(136, 141). Key objectives include: establishing the
role and necessity of the test model; ensuring clarity of the defined goals; defining a prediction model,
i.e. an algorithm for converting the test data into
meaningful predictions of in vivo toxicity; examining the mechanistic relevance and credibility of the
model with respect to those goals; and providing a
description of the limitations of the model.
Where practical validation studies do occur, these
should adhere to best practice standards, designed to
ensure good methodological quality, including, for
example, statistical justifications of sample sizes, randomised allocation to test groups, and blinded treatment and assessment of results. Where possible,
inter-laboratory reproducibility should be demonstrated (136).
Whether validation studies are conducted by practical or weight-of-evidence approaches, experience
has shown that transparency and independence from
commercial, political or other interests should be
maximised through the use of independent experts
and the peer-reviewed publication of outcomes (136).
Scientific validation should lead to the reasoned
overall assessment that sufficient evidence exists to
demonstrate that a model is, or is not, relevant and
reliable for the specified purpose, or that insufficient evidence exists to be reasonably certain either
way. In some cases, an interim assessment can be
made, until further evidence becomes available
(141).
The European Centre for the Validation of
Alternative Methods (ECVAM) was created by the
EC in 1991, to fulfil the requirements of Directive
86/609/EEC on the protection of animals used for
experimental and other scientific purposes. These
requirements state that the EC and its Member
States should actively support the development,
validation and acceptance of methods which could
replace, refine or reduce the use of laboratory animals (142). The US equivalent is the Interagency
Coordinating Committee on the Validation of
Alternative Methods (ICCVAM), which has similar
goals. Despite the high standards required for successful validation, between 1998 and 2007, 21 distinct tests or categories of test methods that could
replace, reduce or refine laboratory animal use,
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had been validated and registered with ECVAM,
and nine had achieved regulatory acceptance
(143).
However, unlike non-animal models, animal models are generally assumed to be reasonably predictive
of human outcomes in preclinical drug development,
toxicity testing, and other fields of biomedical
research, without the need to undergo formal validation studies. Yet the 27 systematic reviews examined
in this study, demonstrate that it is insufficient to
assume that animal models are reliably predictive of
human outcomes, even those in use for long periods,
without subjecting them to critical assessment.
Clearly, formal validation should be consistently
applied to all proposed experimental models,
regardless of their animal, non-animal, historical,
contemporary or possible future status, and models
should be chosen on the basis of critical scientific
review, with appropriate consideration also given to
animal welfare, ethical, legal, economic, and any
other relevant factors.
The Heads of ECVAM and the European
Chemicals Bureau, the EC agencies responsible for
technical aspects of validation and for EU chemicals
regulations, respectively, at that time, made a similar call in 1995, in which they urged that prevalidation and independent assessment be applied with
equal force to all new or modified animal and nonanimal test guidelines (144).

Conclusions
The historical and contemporary paradigm, that animal models are generally reasonably predictive of
human outcomes, provides the basis for their widespread use in toxicity testing and biomedical
research aimed at preventing or developing cures for
human diseases. However, their use persists for historical and cultural reasons, rather than because
they have been demonstrated to be scientifically
valid. For example, many regulatory officials “feel
more comfortable” with animal data (145), and some
even believe that animal tests are inherently valid,
simply because they are conducted in animals (146).
However, most existing systematic reviews have
demonstrated that animal experiments are insufficiently predictive of human outcomes to provide
substantial benefits during the development of
human clinical interventions, or in deriving human
toxicity assessments. In only two of 20 reviews in
which clinical utility was examined, did the authors
conclude that the animal models were either significantly useful in contributing to the development of
clinical interventions, or were substantially consistent with clinical outcomes (84, 85), and one of
these conclusions was contentious. Seven additional
reviews also failed to clearly demonstrate utility in
predicting human toxicological outcomes, such as
carcinogenicity and teratogenicity. Consequently,
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animal data can be generally assumed not to be substantially useful for these purposes.
Likely causes of this inadequacy include inherent
genotypic and phenotypic differences between
human and non-human species, the distortion of
experimental outcomes arising from experimental
environments and protocols, and the poor methodological quality of many animal experiments, as was
apparent in at least 11 reviews. There were no
reviews in which a majority of animal experiments
were of good methodological quality. Some of these
problems might be minimised with concerted effort
(given their widespread prevalence), but the limitations resulting from interspecies differences are
likely to be technically and theoretically impossible
to overcome.
Despite the fact that they have not passed and,
indeed, could not pass, the formal scientific validation
process required of non-animal models prior to regulatory acceptance, most animal models are incorrectly
assumed to be predictive of human outcomes. The
consistent application of formal validation studies to
all test models is clearly warranted, regardless of
their animal, non-animal, historical, contemporary or
possible future status. Experimental model choices
should be based on such critical scientific review,
with appropriate consideration also given to animal
welfare, ethical, legal, economic and other relevant
factors.
Likely benefits would include greater selection of
models truly predictive for human outcomes,
increased safety of people exposed to chemicals that
have passed toxicity tests, increased efficiency during
the development of human pharmaceuticals and
other therapeutic interventions, and decreased
wastage of animal, personnel and financial resources.
In addition, the poor human clinical and toxicological utility of most animal models for which data
exists, in conjunction with their generally substantial
animal welfare and economic costs, justify a ban on
the use of animal models lacking scientific data
clearly establishing their human predictivity or utility.
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